{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:37:48Z","timestamp":1776868668610,"version":"3.51.2"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T00:00:00Z","timestamp":1587168000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T00:00:00Z","timestamp":1587168000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008005","name":"Yonsei University College of Medicine","doi-asserted-by":"publisher","award":["6-2019-0091"],"award-info":[{"award-number":["6-2019-0091"]}],"id":[{"id":"10.13039\/501100008005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatitis B e antigen (HBeAg) seroclearance has been considered as the treatment endpoint in HBeAg-positive patients with chronic hepatitis B (CHB). Although HBeAg seroclearance has been accomplished, some aspects are yet unclear. We investigated the cumulative incidence of hepatocellular carcinoma (HCC) and evaluated hepatitis B surface antigen (HBsAg) seroclearance in patients undergoing nucleos(t) ide analogue (NA)-induced HBeAg seroclearance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective cohort study, 203 patients with CHB were HBsAg and HBeAg seropositive before NA (entecavir or tenofovir) treatment. All patient who experienced NA -induced HBeAg seroclearance were recruited. Patients with documented HBeAg seroclearance were followed-up every 6\u2009months. Baseline characteristics and laboratory results were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The mean age at HBeAg seroclearance was 40\u2009years (range, 20\u201384), and the mean follow-up duration was 5\u2009years (range, 2\u201311). The cumulative incidence of HCC was 1.5 to 11.5% at 1 to 8\u2009years after HBeAg seroclearance. Cirrhosis was the only significant factor for HCC development (hazard ratio [HR], 24.651; confidence interval [CI], 3.018 to 201.365;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.003). The cumulative incidence of HBsAg seroclearance was 3.5 to 18.7% after 1 to 8\u2009years from HBeAg seroclearance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A significant proportion of patients developed HCC after NA-induced HBeAg seroclearance. The presence of liver cirrhosis at the time of HBeAg seroclearance serves as an independent factor for HCC development. Some patients with NA-induced HBeAg seroclearance achieved HBsAg seroclearance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-020-01236-9","type":"journal-article","created":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T15:02:48Z","timestamp":1587222168000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance"],"prefix":"10.1186","volume":"20","author":[{"given":"Hyun Woong","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Il","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saein","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sora","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Young","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwan Sik","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,18]]},"reference":[{"key":"1236_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/cld.728","volume":"12","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Clin Liver Dis (Hoboken). 2018;12:33\u20134.","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"1236_CR2","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370\u201398.","journal-title":"J Hepatol"},{"key":"1236_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3350\/cmh.2019.1002","volume":"25","author":"Korean Association for the Study of the L","year":"2019","unstructured":"Korean Association for the Study of the L. KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol. 2019;25:93\u2013159.","journal-title":"Clin Mol Hepatol"},{"key":"1236_CR4","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/hep.23323","volume":"51","author":"HW Lee","year":"2010","unstructured":"Lee HW, Lee HJ, Hwang JS, et al. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Hepatology. 2010;51:415\u201321.","journal-title":"Hepatology"},{"key":"1236_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1\u201398.","journal-title":"Hepatol Int"},{"key":"1236_CR6","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1002\/hep.21612","volume":"45","author":"CM Chu","year":"2007","unstructured":"Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology. 2007;45:1187\u201392.","journal-title":"Hepatology"},{"key":"1236_CR7","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1053\/j.gastro.2010.04.048","volume":"139","author":"J Liu","year":"2010","unstructured":"Liu J, Yang HI, Lee MH, et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology. 2010;139:474\u201382.","journal-title":"Gastroenterology"},{"key":"1236_CR8","doi-asserted-by":"crossref","unstructured":"Yip TC, Wong GL, Wong VW, et al. Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t) ide analogue-treated patients. J Hepatol. 2017.","DOI":"10.1016\/j.jhep.2017.09.018"},{"key":"1236_CR9","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1053\/j.gastro.2008.05.031","volume":"135","author":"EH Buster","year":"2008","unstructured":"Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology. 2008;135:459\u201367.","journal-title":"Gastroenterology"},{"key":"1236_CR10","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3350\/cmh.2018.0106","volume":"25","author":"LY Liang","year":"2019","unstructured":"Liang LY, Wong GL. Unmet need in chronic hepatitis B management. Clin Mol Hepatol. 2019;25:172\u201380.","journal-title":"Clin Mol Hepatol"},{"key":"1236_CR11","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","volume":"63","author":"GA Kim","year":"2014","unstructured":"Kim GA, Lim YS, An J, et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut. 2014;63:1325\u201332.","journal-title":"Gut"},{"key":"1236_CR12","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1053\/gast.2002.36026","volume":"123","author":"YC Chen","year":"2002","unstructured":"Chen YC, Sheen IS, Chu CM, et al. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology. 2002;123:1084\u20139.","journal-title":"Gastroenterology"},{"key":"1236_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3350\/cmh.2017.0104","volume":"23","author":"EJ Cho","year":"2017","unstructured":"Cho EJ, Kim SE, Suk KT, et al. Current status and strategies for hepatitis B control in Korea. Clin Mol Hepatol. 2017;23:205\u201311.","journal-title":"Clin Mol Hepatol"},{"key":"1236_CR14","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and Management of Hepatocellular Carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723\u201350.","journal-title":"Hepatology"},{"key":"1236_CR15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182\u2013236.","journal-title":"J Hepatol"},{"key":"1236_CR16","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/hep.29874","volume":"68","author":"J Fung","year":"2018","unstructured":"Fung J, Cheung KS, Wong DK, et al. Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance. Hepatology. 2018;68:462\u201372.","journal-title":"Hepatology"},{"key":"1236_CR17","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/MCG.0000000000000478","volume":"50","author":"MF Yuen","year":"2016","unstructured":"Yuen MF, Ahn SH, Chen DS, et al. Chronic hepatitis B virus infection: disease revisit and management recommendations. J Clin Gastroenterol. 2016;50:286\u201394.","journal-title":"J Clin Gastroenterol"},{"key":"1236_CR18","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1053\/j.gastro.2018.10.027","volume":"156","author":"YH Yeo","year":"2019","unstructured":"Yeo YH, Ho HJ, Yang HI, et al. Factors associated with rates of HBsAg Seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis. Gastroenterology. 2019;156:635\u201346 e639.","journal-title":"Gastroenterology"},{"key":"1236_CR19","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.jhep.2017.06.019","volume":"67","author":"TC Yip","year":"2017","unstructured":"Yip TC, Chan HL, Wong VW, et al. Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. J Hepatol. 2017;67:902\u20138.","journal-title":"J Hepatol"},{"key":"1236_CR20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1001\/jamaoncol.2018.4070","volume":"5","author":"J Choi","year":"2019","unstructured":"Choi J, Kim HJ, Lee J, et al. Risk of hepatocellular carcinoma in patients treated with Entecavir vs Tenofovir for chronic hepatitis B: a Korean Nationwide cohort study. JAMA Oncol. 2019;5:30\u20136.","journal-title":"JAMA Oncol"},{"key":"1236_CR21","doi-asserted-by":"publisher","first-page":"816","DOI":"10.3346\/jkms.2005.20.5.816","volume":"20","author":"SH Bae","year":"2005","unstructured":"Bae SH, Yoon SK, Jang JW, et al. Hepatitis B virus genotype C prevails among chronic carriers of the virus in Korea. J Korean Med Sci. 2005;20:816\u201320.","journal-title":"J Korean Med Sci"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-020-01236-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-020-01236-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-020-01236-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T19:07:06Z","timestamp":1618686426000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-020-01236-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,18]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1236"],"URL":"https:\/\/doi.org\/10.1186\/s12876-020-01236-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.16279\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.16279\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.16279\/v1","asserted-by":"object"}]},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,18]]},"assertion":[{"value":"13 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board of Gangnam Severance Hospital. As this study was a retrospective design, written consent was not required.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Hyun Woong Lee is a member of the editorial board of BMC gastroenterology.The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"113"}}